All In Biotech

Free tool

FAERS Monitor: Penpulimab-Kcqx

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761258 or its brand name (Penpulimab-Kcqx, Penpulimab-Kcqx). Reports on generic versions are filed under their own applications.

Reports

98

Serious

98

100% of reports

Hospitalization

43

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia13
  • myelosuppression13
  • rash11
  • hypothyroidism10
  • leukopenia10
  • nausea10
  • thrombocytopenia10
  • anaphylactic shock9
  • diarrhoea9
  • hepatic function abnormal9
  • chest discomfort8
  • vomiting8
  • pruritus7
  • pyrexia7
  • alanine aminotransferase increased6

Reports by year received

View as table
YearReports
20213
20225
20235
20249
202512
202663

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,061 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal1377.546.7908
anaphylactic shockSignal975.040.2585
hypothyroidismSignal1067.237.4589
hepatic function abnormalSignal951.827.8399
leukopeniaSignal1042.923.9369
alanine aminotransferase increasedSignal621.09.795
thrombocytopeniaSignal1019.210.7156
chest discomfortSignal816.88.6104
anaemiaSignal1314.68.8153
rashSignal115.43.136
pyrexiaSignal74.32.115
pruritusSignal73.91.913
vomitingSignal83.71.913
diarrhoeaSignal93.01.610
nauseaSignal102.71.510

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.